Rates of Acquisition of Pneumococcal Colonization and Transmission Probabilities, by Serotype, Among Newborn Infants in Kilifi District, Kenya by Tigoi, Caroline C. et al.
MAJOR ARTICLE
Rates of Acquisition of Pneumococcal
Colonization and Transmission Probabilities,
by Serotype, Among Newborn Infants in Kiliﬁ
District, Kenya
Caroline C. Tigoi,
1 Hellen Gatakaa,
1 Angela Karani,
1 Daisy Mugo,
1 Stella Kungu,
1 Eva Wanjiru,
1 Jane Jomo,
1
Robert Musyimi,
1 John Ojal,
1 Nina E. Glass,
2 Osman Abdullahi,
1,3 and J. Anthony G. Scott
1,4
1Kenya Medical Research Institute–Wellcome Trust Research Programme, Kiliﬁ;
2Department of Surgery, Langone Medical Center, New York
University;
3Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts; and
4Nufﬁeld Department
of Clinical Medicine, Oxford University, United Kingdom
Background. Herd protection and serotype replacement disease following introduction of pneumococcal con-
jugate vaccine (PCV) are attributable to the vaccine’s impact on colonization. Prior to vaccine introduction in
Kenya, we did an epidemiological study to estimate the rate of pneumococcal acquisition, by serotype, in an un-
colonized population.
Methods. Nasopharyngeal swab specimens were taken from newborns aged ≤7 days and weekly thereafter for
13 weeks. Parents, and siblings aged <10 years, were swabbed at monthly intervals. Swabs were transported in
skim milk-tryptone-glucose-glycerin and cultured on gentamicin blood agar. Pneumococci were serotyped by the
Quellung reaction. We used survival analysis and Cox regression analysis to examine serotype-speciﬁc acquisition
rates and risk factors and calculated transmission probabilities from the pattern of acquisitions within the family.
Results. Of 1404 infants recruited, 887 were colonized by 3 months of age, with the earliest acquisition de-
tected on the ﬁrst day of life. The median time to acquisition was 38.5 days. The pneumococcal acquisition rate
was 0.0189 acquisitions/day (95% conﬁdence interval, .0177–.0202 acquisitions/day). Serotype-speciﬁc acquisition
rates varied from 0.00002–0.0025 acquisitions/day among 49 different serotypes. Season, coryza, and exposure to
cigarettes, cooking fumes, and other children in the home were each signiﬁcant risk factors for acquisition. The
transmission probability per 30-day duration of contact with a carrier was 0.23 (95% CI, .20–.26).
Conclusions. Newborn infants in Kiliﬁ have high rates of nasopharyngeal acquisition of pneumococci. Half of
these acquisitions involve serotypes not included in any current vaccine. Several risk factors are modiﬁable
through intervention. Newborns represent a consistent population of pneumococcus-naive individuals in which to
estimate the impact of PCV on transmission.
Introductionofpneumococcalconjugatevaccines(PCVs)
has reduced childhood invasive pneumococcal disease
(IPD) caused by vaccine serotypes in all populations
studied. However, the indirect effects of PCV, herd
protection and serotype replacement disease, have
been much more variable [1]. Serotype replacement
disease has not occurred in some populations, while in
others it has almost negated the beneﬁcial direct effect
of PCV [2, 3].
The GAVI Alliance is supporting PCV introduction
in all developing countries, and the magnitude of the
indirect effects of PCV will be a signiﬁcant factor de-
termining the value of these investments. The broad
surveillance systems for IPD that have characterized
the impact of PCV in developed countries [4, 5] were
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on IPD incidence are scarce. However, because indirect vaccine
effects are mediated by changes in nasopharyngeal carriage, and
because carriage is more amenable to study than IPD, it may be
possible to model the effect of vaccine introduction on disease
by monitoring its effect on carriage and transmission [6, 7].
A 10-valent PCV (containing serotypes 1, 4, 5, 6B, 7F, 9V,
14, 18C, 19F, and 23F) was introduced into the childhood
immunization program of Kenya in February 2011. Before in-
troduction of the vaccine, we studied uninfected newborn
infants to examine the baseline rate of acquisition of naso-
pharyngeal colonization. Because each pneumococcal serotype
exhibits a different epidemiological pattern [8], we studied
acquisition rates for the 28 most common serotypes. Acqui-
sition rates describe the experience of the newborn without
reference to the source of infection. To estimate the trans-
mission probability, deﬁned as the probability that contact
between a colonized relative and an uninfected newborn
results in colonization of the newborn [9], we also studied the
carriage status of household family members.
METHODS
Study Population
The study was conducted at Kiliﬁ District Hospital (KDH) on
the Indian Ocean coast of Kenya among families who were
residents of the Kiliﬁ Health and Demographic Surveillance
System (KHDSS) [10]. This is a longitudinal surveillance of
approximately 250000 people living in a well-deﬁned geo-
graphic area around KDH, with an annual birth cohort of
approximately 8000. Mother-infant pairs were recruited after
delivery of the infant in the KDH maternity department,
when the infant was registered in the KHDSS, or when the
infant was brought to the KDH vaccination clinic, if the visit
occurred ≤7 days after birth. We then visited the whole family
at home and invited them to participate. Infants were ex-
cluded from the study if they had >6 siblings aged <10 years
but were not excluded if their relatives declined to participate.
Study Design
We collected nasopharyngeal swab specimens from newborns
twice weekly for 2 weeks and weekly thereafter. Follow-up
ceased when a pneumococcus was cultured from an infant's
swab or 13 weeks after study entry, whichever was sooner. Na-
sopharyngeal swab specimens were taken from the infant’s
mother, father, and siblings at recruitment and every 4 weeks
thereafter until the index infant was colonized or reached 9
weeks of age, whichever was sooner. By questionnaire, we as-
certained household size and location, socioeconomic variables,
and results of human immunodeﬁciency virus (HIV) testing
performed for the mother antenatal clinic. At each maternal
contact, we ascertained the following information for the infant:
the number of household members and siblings, breast-
feeding status, cigarette and cooking smoke exposure, symp-
toms of upper respiratory tract infection, and antibiotic use.
Laboratory Assay
Specimens were collected and processed following standard
methods [11]. Dacron-tipped ﬂexible wire swabs were inserted
into the posterior nasopharynx, rotated slowly for 1 second,
and withdrawn. Swab tips were removed with wire cutters and
transported to the laboratory within 8 hours in skim milk-
tryptone-glucose-glycerin (STGG) medium, where they were
cultured directly. The STGG was vortexed for 20 seconds to
extract the nasopharyngeal specimen from the swab, and a
10-μL sample was inoculated onto blood agar with 2.5 μg/mL
gentamicin and incubated overnight at 37°C in 5% CO2. Pneu-
mococci were identiﬁed by α-hemolysis, optochin sensitivity,
and presence of capsules. Pneumococci were serotyped by the
Quellung reaction, using polyclonal rabbit antisera (Statens
Seruminstitut, Copenhagen, Denmark). We serotyped 4 pneu-
mococcal colonies per plate, selecting morphologically distinct
colonies when possible. For the infant’s relatives we analyzed
multiple-serotype carriage because all colonizing serotypes
constitute an infection risk to the infant, but for the infant we
only analyzed the dominant colonizing serotype because the
risk of simultaneous acquisition of two serotypes is small. We
performed quality control of STGG and gentamicin blood agar
to ensure sterility and the ability to support pneumococcal
growth.Serotypingwasmonitoredbya2-monthlyinternalqual-
ity assurance scheme, using a library of standard pneumococci.
Analysis
The analyses were performed using Stata v11.2 (StataCorp,
College Station, TX). Acquisition rates were estimated by sur-
vival analysis of infection-free periods, deﬁned by the mid-
point of the interval in which the swab result switched from
negative to positive. Infants whose ﬁrst swab specimen tested
positive were assumed to have been negative for pneumococci
at birth. Infants who were lost to follow-up throughout the
study or who remained untraceable after 98 days were cen-
sored at the time their last swab specimen was collected.
We explored the risk factors for acquisition of pneumococ-
cal colonization by use of Cox regression to examine both
ﬁxed covariates (eg, month of birth) and time-dependent cov-
ariates (eg, coryza at the time of swabbing). Variables with a
signiﬁcant association (P<.1) on univariate analyses were in-
cluded in a backward, stepwise regression model and rejected
at the P≥.05 level on the basis of likelihood ratio tests. We
examined the proportional hazards assumption by testing the
slope of Schoenfeld residuals over time and by identifying par-
allelism in log-log hazard plots.
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Because pneumococci are poorly transmissible, we monitored
family members at monthly intervals and set the interval for a
relevant contact as 30 days of cohabitation. We identiﬁed these
contact periods between relatives and newborns and followed
the infection-free survival of the infant for up to 30 days. The
start of each contact period was deﬁned as the date on which a
pneumococcus-positive swab sample was collected from the
relative, and the end of the contact period was deﬁned by the
date on which the next swab specimen was collected from that
same relative, the date on which acquisition of any pneumo-
coccus was detected in the infant, the date on which the last
pneumococcus-negative swab specimen was collected from the
infant (if the infant was lost to follow-up), or 30 days after the
collection of the initial swab specimen from the relative, which-
ever was sooner. We assumed that a relative colonized at the
outset remained infectious throughout the contact period.
Because the contact periods varied in duration (1–30 days), we
used survival analysis to estimate the daily hazard of acqui-
sition of a homologous serotype in the newborn. Analysis time
began at the start of each contact period, and we measured
hazard rates per 30 days. If the relative’s initial swab specimen
was positive for >1 serotype, we treated these serotypes as inde-
pendent exposures and duplicated the contact period record. If
an infant was simultaneously exposed to >1 relative with the
same serotype, we weighted the record with the reciprocal of
the number of simultaneously infected relatives. We explored
variation in the transmission hazard rate by type of relative,
age of sibling, and sex of newborn. We converted the hazard of
homologous acquisition (λ) to transmission probabilities (P),
using P=1−e
−λ.
The KEMRI National Ethical Review Committee and the
Oxford Tropical Research Ethics Committee approved the
study, and written informed consent was obtained from all
adult participants and from the mothers of participating
infants and their siblings.
RESULTS
Recruitment began 29 June 2006 and ended 3 March 2009,
and the last swab was obtained on 14 May 2009. In total, 2080
pneumococcal isolates were cultured from 12610 swabs.
Figure 1 shows the ﬂow of recruitment and follow-up. The
mean (median) age of infants at recruitment was 2.1 days
(1 day). Of 1404 children recruited, 46 infants (3.3%) were
already colonized at the time their ﬁrst swab specimen was
collected. The prevalence of existing colonization increased
linearly, from 0.86% (5 of 583) on day 1 to 9.7% (10 of 103)
on day 7 of life (Supplementary Table S1). We recruited 1372
mothers, 221 fathers, and 1412 siblings, of whom 1357 (99%),
189 (86%), and 1268 (90%), respectively, were recruited within
7 days of the infant. We were unable to locate 355 fathers, and
828 fathers declined to participate.
Rates of Acquisition
The mean (median) interval between swab collection among
newborn participants was 7.04 days (7 days); the mean
(median) interval used to estimate acquisition was 9.2 days
(7 days). A total of 887 infections were observed during
46947 days of risk, giving an acquisition hazard rate of 0.0189
per child per day (95% conﬁdence interval [CI], .0177–.0202).
The observed median time to acquisition was 38.5 days.
Despite a good approximation to an exponential curve
(Figure 2), the hazard rate was 25% higher (0.0225; 95% CI,
.0197–.0257) in the second half of follow-up time than in the
ﬁrst half (0.0180; 95% CI, .0166–.0194; P=.0046). We used
nonparametric survival techniques for all further analyses.
Figure 1. Flow of subjects recruited into the study. The timing of
acquisitions and losses to follow-up are detailed in Supplementary
Table S2. Losses to follow-up were mainly due to withdrawal of consent.
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Among 887 pneumococci acquired in the study, there were 49
different serotypes; one pneumococcus died before it could be
serotyped. The hazard rate for acquisition of individual sero-
types (Table 1 and Supplementary Table S3) varied from
0.0025/day for serotype 19F, the most common serotype, to
0.000021/day for the rarest serotypes. The acquisition rate for
serotypes contained in the 13-valent PCV (which includes sero-
types 3, 6A, and 19A, in addition to PCV10 serotypes) was
half of the total pneumococcal acquisition rate (Table 1).
Risk Factors for Acquisition
Univariate hazard ratios for potential risk factors are shown in
Table 2. In the ﬁnal model (Table 3), there was a single signiﬁ-
cant interaction between coryza observed at the previous visit
and the number of siblings (P=.019, by the likelihood ratio
test). Prior coryza did not have any effect on the hazard of
acquisition in the absence of siblings but enhanced the hazard
associated with siblings, at least for newborns with 1–4 sib-
lings. The proportional hazards assumptions were met by all
variables.
Serotype Prevalence in Family Members
Among 4387 swab specimens taken from family members,
1120 (26%) were positive for pneumococci, with 170 of 2144
swab specimens (7.93%) from mothers, 35 of 284 (12%) from
fathers, and 915 of 1959 (46.7%) from siblings aged <10 years
yielding positive results. Two serotypes were observed simul-
taneously in swab specimens from 69 siblings, 3 fathers, and
1 mother. In total, we observed 1193 pneumococci in the
families of index children. The distribution of serotypes
varied substantially across the 3 groups (ie, newborns, siblings,
and parents; Supplementary Table S4).
Transmission Probability Within Families
There were 874 periods of contact of 1–30 days in duration
between relatives and newborns in which the relative was colo-
nized at the outset. In 54, the relative was cocolonized with 2
serotypes, giving 928 exposure periods for potential serotype-
speciﬁc transmission. The mean (median) duration of these
episodes was 21.3 days (26.5 days), and they were terminated
Table 1. Rate of Pneumococcal Acquisition Among Newborn
Infants, by Serotype, in Decreasing Order of Rates and in Groups
of Serotypes Contained in Vaccine Formulations
Serotype
Acquisitions
(No.)
Hazard Rate
(per Day) 95% CI
19F 119 0.00254 .00212–.00303
6A 70 0.00149 .00118–.00189
6B 59 0.00126 .00097–.00162
23F 58 0.00124 .00096–.00160
23B 47 0.00100 .00075–.00133
14 37 0.00079 .00057–.00109
35B 37 0.00079 .00057–.00109
11A 33 0.00070 .00050–.00099
15B 28 0.00060 .00041–.00086
15C 26 0.00055 .00038–.00081
15A 25 0.00053 .00036–.00079
34 25 0.00053 .00036–.00079
19A 24 0.00051 .00034–.00076
10A 23 0.00049 .00033–.00074
3 21 0.00045 .00029–.00069
9V 20 0.00043 .00028–.00066
13 19 0.00041 .00026–.00063
19B 19 0.00041 .00026–.00063
21 19 0.00041 .00026–.00063
7C 17 0.00036 .00023–.00058
20 16 0.00034 .00021–.00056
16F 15 0.00032 .00019–.00053
4 15 0.00032 .00019–.00053
18C 12 0.00026 .00015–.00045
23A 12 0.00026 .00015–.00045
33B 12 0.00026 .00015–.00045
38 12 0.00026 .00015–.00045
33D 11 0.00023 .00013–.00042
PCV7 types 320 0.00682 .00611–.00761
1, 5, 7F 9 0.00019 .00010–.00037
3, 6A, 19A 115 0.00245 .00204–.00294
All other
types
443 0.00944 .00860–.01036
All 887 0.01889 .01769–.02018
The total time at risk was 46947 days. Analyses are shown for all serotypes
in which >10 acquisitions were observed in the study. Serotypes contained
in PCV7 are 4, 6B, 9V, 14, 18C, 19F, and 23F. The results of the analyses of
all serotypes are shown in Supplementary Table S3.
Abbreviations: CI, confidence interval; PCV7, 7-valent pneumococcal
conjugate vaccine.
Figure 2. Survival curve and exponential ﬁt to infection-free duration
among newborn infants followed up for pneumococcal colonization.
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Risk factor Acquisitions (No.) All
a Infants (No.) Hazard Rate 95% CI P
Study period (per month) 887 1404 0.999 .997–1.037 <.00005
Month 887 1404 <.00005
Jan …… 1.00
Feb …… 0.85 .58–1.23
Mar …… 0.88 .62–1.25
Apr …… 0.92 .65–1.3
May …… 0.91 .64–1.3
Jun …… 1.27 .9–1.79
Jul …… 1.77 1.29–2.42
Aug …… 1.46 1.05–2.02
Sep …… 1.50 1.07–2.1
Oct …… 1.26 .89–1.77
Nov …… 0.94 .65–1.35
Dec …… 0.66 .44–.99
Male sex 887 1404 0.97 .85–1.11 .68
Mother tested positive for HIV 515 923 1.11 .78–1.56 .5792
No. of smokers in the house 835 1191 .0276
0 …… 1.00
1 …… 1.26 1.08–1.48
2 …… 1.54 .69–3.43
Type of fuel used for cooking 814 1167 .0018
Firewood …… 1.00
Charcoal …… 0.52 .3–0.88
Paraffin …… 0.77 .61–.97
Gas …… 2.11 .94–4.72
Breast-feeding at this visit 880 1401 1.21 .65–2.27 .5279
Breast-feeding at last visit 880 1402 1.03 .58–1.83 .907
Cough observed at this visit 887 1404 1.65 1.34–2.03 <.00005
Coryza observed at this visit 887 1404 1.81 1.55–2.13 <.00005
Coryza observed at last visit 887 1404 1.46 1.21–1.76 .0001
Obvious nasal mucous at NP swab 887 1404 1.36 1.03–1.8 .0354
Caregiver reports history of cough in infant 846 1400 1.97 1.42–2.73 .0002
Caregiver reports history of coryza in infant 800 1395 1.64 1.23–2.18 .0017
No. of siblings aged <10 years 887 1403 <.00005
0 …… 1.00
1–2 …… 1.69 1.41–2.02
3–4 …… 2.03 1.66–2.47
5–6 …… 1.47 1.02–2.13
No. of others aged <10 years in household 835 1194 <.00005
0 …… 1.00
1 …… 1.40 1.11–1.76
2 …… 1.66 1.35–2.05
3 …… 1.72 1.37–2.15
4 …… 2.25 1.72–2.95
≥5 …… 1.93 1.33–2.79
No. of others aged >10 years in household
0 834 1190 1.00 .697
1 …… 0.93 .74–1.17
2 …… 1.03 .86–1.24
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acquisition in the newborn in 186, 329, and 413 episodes,
respectively. In 60 episodes homologous transmission took
place from 1 of 2 simultaneously colonized relatives, and in 9
episodes it took place from 1 of 3 simultaneously colonized
relatives.
The baseline homologous acquisition hazard for contact with
a colonized relative was 0.26 (95% CI .23–.31) per 30-day
period, giving a calculated transmission probability of 0.23
(95% CI, .20–.26) per 30-day period (Table 4). The crude trans-
mission probability (calculated as the number of infections
divided by the number of exposure episodes) was 0.20 (186 in-
fections per 928 exposure episodes), although some of these
episodes were <30 days. Overall, the homologous acquisition
hazard was slightly greater among female infants than male
infants, but this varied with the type of potentially infecting
contact. The hazard ratio for (male) sex was 1.49 in association
with maternal contact periods and 0.74 in association with
sibling contact periods. The study was not designed to test
interactions between child sex and relative type, and the test for
interaction was not signiﬁcant (P=.10). In sibling contact
periods, the age of the sibling did not affect the probability of
homologous acquisition in the infant (P=.37). Transmission
probabilities for individual serotypes are shown in Table 4.
DISCUSSION
In one of the largest carriage studies ever conducted, we have
estimated the rate of acquisition of colonization of 28 sero-
types of pneumococcus among a susceptible uninfected
population—newborn infants—and used acquisition condi-
tional on contact with colonized relatives to estimate serotype-
speciﬁc transmission probabilities.
Evidence from vaccine studies [12–14] and randomized
controlled trials [15] suggests that the indirect effects of PCV
on IPD are brought about by changes in pneumococcal car-
riage. Because of the delayed impact of PCV on carriage
prevalence, it is assumed that PCV reduces the acquisition of
vaccine serotypes without necessarily affecting carriage dur-
ation [12, 16]. PCV also reduces the carriage density of vaccine
Table 2 continued.
Risk factor Acquisitions (No.) All
a Infants (No.) Hazard Rate 95% CI P
3 …… 0.88 .69–1.12
4–5 …… 0.95 .74–1.21
6–9 …… 0.87 .56–1.36
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; NP, nasopharyngeal.
a Data are for all infants for whom the risk factor was known.
Table 3. Final Model of Risk Factors for Acquisition of Pneumo-
coccal Colonization
Risk Factor
Adjusted
Hazard Ratio 95% CI
Month
Jan 1.00
Feb 0.90 .61–1.33
Mar 0.89 .61–1.30
Apr 0.96 .66–1.40
May 0.96 .66–1.39
Jun 1.40 .97–2.02
Jul 1.72 1.22–2.41
Aug 1.59 1.12–2.25
Sep 1.53 1.07–2.18
Oct 1.35 .94–1.94
Nov 1.06 .72–1.57
Dec 0.65 .42–1.00
Cigarette smokers in household
Per smoker 1.20 1.04–1.39
Fuel used for cooking
Firewood 1.00
Charcoal 0.49 .29–.83
Paraffin 0.75 .59–.94
Gas 2.24 .99–5.08
Coryza observed this visit
No 1.00
Yes 1.73 1.46–2.06
Coryza not observed at last visit
No. of siblings aged <10 years
0 1.00
1–2 1.53 1.23–1.89
3–4 1.80 1.41–2.32
5–6 1.36 .89–2.09
Coryza observed at last visit
No. of siblings aged <10 years
0 1.02
1–2 2.42 1.79–3.27
3–4 2.03 1.35–3.04
5–6 0.40 .10–1.65
No. of other children <10 years in
household
Per child 1.08 1.02–1.14
Abbreviation: CI, confidence interval.
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vaccine coverage, reduced acquisition of vaccine serotypes
leads to reduced prevalence, and this, in turn, reduces trans-
mission. This negative feedback cycle anticipates a decline to
extinction that can be predicted by the transmission prob-
ability, contact probability, vaccine efﬁcacy against carriage,
and vaccine coverage. A similar approach can be taken to
predict the commensurate rise in nonvaccine serotype carriage
leading to serotype-replacement disease [17]. However, at
present both approaches rely on limited empirical data, and
most models are constrained to a handful of common sero-
types [18, 19]. The objectives of this study were to provide
acquisition rates and transmission probabilities for a wide
range of serotypes in the prevaccine era to populate such
models. We also aimed to describe the epidemiology of pneu-
mococcal acquisition in a highly vulnerable population.
It has been known for 80 years that pneumococci can colo-
nize infants on the day of birth [20]; between 1930–1950, 30%
of European newborns acquired pneumococci by the age of
12–15 days [20, 21]. In America, in the 1980s, the mean age of
initial pneumococcal colonization was 6 months [22]; in Papua
New Guinea, by contrast, 60% of infants were colonized within
15 days of age, and all infants acquired infection by 3 months
of age [23, 24]. Similarly, in The Gambia half of all newborns
were colonized within 24 days [25]. Newborns in Kiliﬁ were
colonized less rapidly than in these other tropical environ-
ments: at 1 week of age, 10% of children were already colo-
nized, and the median age at colonization was 38.5 days. The
acquisition rate increased 25% between the ﬁrst and second 6
weeks of life. This may be a function of follow-up losses (in
24% of infants), or it may simply signal that newborns are pro-
tected against acquisition either by passive maternal antibody
or by behavioral factors limiting their exposure to infection.
The study provides relatively precise estimates of acquisition
rates for 28 pneumococcal serotypes. The serotypes included
in the 10- and 13-valent PCVs accounted for 37%–50% of all
Table 4. Conditional Pneumococcal Acquisition Hazard Rates
and Transmission Probabilities
Subset of
Observations
Contact
Periods
(No.)
Risk
Interval
(×30
Days)
Hazard
Rate 95% CI
Transmission
Probability
All risk
episodes
928 571.9 0.26 .23–0.31 0.23
For female
infants
407 247.6 0.29 .23–0.36 0.25
For male
infants
521 324.3 0.24 .20–0.30 0.22
Fathers 31 20.2 0.10 .03–0.56 0.09
Mothers 128 87.5 0.27 .19–0.40 0.24
To female
infants
62 45.0 0.22 .12–0.42 0.20
To male
infants
66 42.4 0.33 .20–0.55 0.28
Siblings 769 464.3 0.27 .23–0.32 0.23
To female
infants
333 193.3 0.32 .25–0.40 0.27
To male
infants
436 271.0 0.23 .19–0.30 0.21
Siblings, by age
0–1 year 97 59.5 0.34 .22–0.53 0.29
2–3 years 350 213.1 0.26 .21–0.34 0.23
4–5 years 198 120.2 0.27 .20–0.38 0.24
6–7 years 89 52.2 0.19 .11–0.35 0.17
8–9 years 35 19.4 0.31 .15–0.73 0.27
Serotype
3 41 24.8 0.04 .01–0.39 0.04
4 19 12.2 0.25 .08–1.07 0.22
5 7 4.6 0.22 .04–1.96 0.20
6A 78 48.2 0.31 .20–0.51 0.27
6B 61 35.6 0.20 .10–0.43 0.18
7C 12 7.6 0.13 .04–0.12 0.12
9V 24 14.3 0.28 .11–0.90 0.24
10A 29 20.5 0.20 .08–0.64 0.18
11A 43 28.4 0.25 .12–0.57 0.22
13 33 22.6 0.18 .07–0.55 0.16
14 34 22.2 0.23 .10–0.64 0.20
15A 23 15.7 0.26 .10–0.85 0.23
15B 20 11.8 0.34 .13–1.04 0.29
15C 40 25.8 0.31 .16–0.64 0.27
16F 13 10.0 0.20 .05–1.65 0.18
18C 19 11.0 0.27 .09–1.03 0.24
19A 27 16.2 0.25 .10–0.78 0.22
19B 12 5.2 0.58 .20–1.98 0.44
19F 104 67.3 0.39 .27–0.56 0.32
20 22 15.7 0
21 17 9.9 0
23A 11 9.0 0
23B 33 16.8 0.54 .30–1.00 0.41
23F 43 24.9 0.44 .25–0.81 0.36
33B 13 9.8 0.20 .05–1.72 0.19
34 41 25.6 0.16 .06–0.49 0.14
Table 4 continued.
Subset of
Observations
Contact
Periods
(No.)
Risk
Interval
(×30
Days)
Hazard
Rate 95% CI
Transmission
Probability
35B 37 20.6 0.29 .14–0.68 0.25
38 11 5.6 0.18 .03–1.64 0.16
The hazard rates and transmission probabilities for infant acquisition of a
homologous serotype reflect a 30-day contact period with a colonized family
member. Only serotypes with at least 120 days of risk time (4× 30 days) are
shown here: data on all serotypes are shown in Supplementary Table S5.
Crude transmission probabilities can be obtained as the ratio of acquisitions
to exposure periods.
Abbreviation: CI, confidence interval.
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in this study correlated well with those estimated for older
children (age, 3–59 months) in the same setting (r =0.87;
P<.00005), although the rates in the older children are on
average 50% greater [26]. Our expectation, at the outset, was
that acquisition rates would be higher in uninfected newborns
than in the general childhood population because intraspecies
competition among individuals with prevalent carriage would
lower population mean rates, compared with rates in the unin-
fected group [27].
Our results provide credible transmission probabilities for
approximately 25 different serotypes. These vary from 0.04
per 30 contact-days for serotype 3 to 0.44 per 30 contact-days
for serotype 19B. Because the contact periods varied in dur-
ation, we estimated transmission probabilities, assuming a
constant rate of transmission over time. Time-dependent pro-
cesses that inﬂuence transmission, like acquired immunity in
the relative or declining passive immunity in the newborn, un-
dermine this assumption. However, the major factors in trans-
mission, such as the occurrence of a viral upper respiratory
tract infection in the transmitter [28], are not associated with
the existing duration of contact between the pairs.
Age and household size are strong determinants of mixing in
social contact studies and are likely to impact transmission [29].
In our study, mothers and siblings were equally effective in
transmitting pneumococci to infants, but siblings were more
effective in transmitting to a female infant and mothers to a
male infant. Toddlers are thought to be the engine of trans-
mission because they have a high prevalence of carriage and
poor hygiene, but we observed that carriers were equally effec-
tive transmitters from birth to 9 years of age. In Africa, this
has important implications for the strategy of PCV introduc-
tion because the prevalence of carriage remains high through
9 years of age [30–32]. To vaccinate the majority of effective
transmitters and establish herd protection would take nearly
10 years if immunization targeted only infants.
The risk factors for acquisition conﬁrm that the household
is an important vehicle for transmission and that children in the
household, regardless of family membership, are the primary
source. Coryza is a known risk for carriage prevalence [32],
but it has not been possible to distinguish whether coryza en-
hances the risk of colonization or just the detection of coloni-
zation. Our results suggest that both interpretations apply.
Coryza at the end of a risk period is associated with acqui-
sition (higher detection), but so too is coryza at the beginning
of a risk period. However, preexisting coryza only enhanced
acquisition among infants who had 1–4 siblings, suggesting
that the symptoms of coryza may facilitate pneumococcal at-
tachment in exposed individuals–as has been suggested in
animal models [33]. Smoky ﬁrewood, as compared to charcoal
or parafﬁn, is associated with acquisition risk, as is cigarette
smoke exposure; smoking is a known risk factor for pneumo-
coccal carriage [34] and, like indoor cooking smoke [35], is
amenable to intervention. Finally, the acquisition hazard illus-
trates a monthly seasonal pattern that mirrors the colonization
prevalence among 3–59-month-old children in the same com-
munity very closely [32].
The study was unable to provide a comprehensive description
of household transmission, particularly from fathers. In the
KHDSS, adult males are present in the household relatively in-
frequently because they out-migrate for work [10].Furthermore,
fathers were much less likely than mothers to consent to
provide a series of 3 swab specimens. Our study also ignores the
role of the wider community in pneumococcal transmission,
although elsewhere, community-based acquisition is trivial,
compared with intrafamilial acquisition [18].The study did seek
multiple serotypes among colonized household members, but
the methods used are less sensitive than more recently available
techniques [36]. Populations of pneumococci that exist at much
lower densities in the nasopharynx are likely to have a trans-
mission probability that is proportionately lower, and this will
minimize the impact of misclassiﬁcation on the results.
This study has provided acquisition rates for 28 different
pneumococcal serotypes in young infants; half of all acqui-
sitions observed were of serotypes included in the 13-valent for-
mulation of PCV. The acquisition rates are similar to those
observed in older children in the same population [26], and the
risk factors include cooking and cigarette smoke, season,
contact with children in the household, and symptoms of upper
respiratory tract infection. This is the ﬁrst study to provide cred-
ible transmission probabilities for a wide range of serotypes.
These parameters will be valuable to modelers attempting to de-
scribe and understand the indirect effects of conjugate vaccines.
The study also sets the baseline for epidemiological observations
of indirect vaccine effects following PCV introduction in Kenya.
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